Gallium maltolate

DRUG4 trials

Sponsors

Titan Pharmaceuticals, Imaging Biometrics, LLC, Sarah Rumler, Medical College of Wisconsin

Conditions

Atypical Teratoid Rhabdoid Tumors (ATRT)Bladder NeoplasmsDIPGDiffuse Intrinsic Pontine Gliomas (DIPG)Diffuse Midline GliomaGlioblastomaGlioblastoma MultiformeHigh Grade Gliomas

Early Phase 1

Oral Gallium Maltolate for Recurrent Glioblastoma

Not yet recruitingNCT07515924

Medical College of WisconsinGlioblastoma

Start: 2026-06-01End: 2027-09-01Target: 8Updated: 2026-04-07

Phase 1

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

TerminatedNCT00050687

Titan PharmaceuticalsBladder Neoplasms, Lymphoma, Multiple Myeloma +1

Start: 2001-06-30End: 2005-03-31Updated: 2011-01-28

Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor

Not yet recruitingNCT07331064

Sarah RumlerAtypical Teratoid Rhabdoid Tumors (ATRT), Diffuse Intrinsic Pontine Gliomas (DIPG), Diffuse Midline Glioma +2

Start: 2026-05-15End: 2031-05-15Target: 15Updated: 2026-01-09

Unknown Phase

Expanded Access to Gallium Maltolate (GaM)

Imaging Biometrics, LLCGlioblastoma, Glioblastoma Multiforme, Refractory Glioblastoma

Updated: 2026-06-08